GILD vs PYXS
GILD: A leading biopharmaceutical innovator specializing in life-saving HIV therapies and complex CAR T-cell cancer treatments. PYXS: A clinical-stage oncology company developing a novel antibody-drug conjugate targeting the tumor microenvironment to treat difficult-to-treat solid tumors like HNSCC.
Side-by-side fundamentals
| Metric | GILD | PYXS | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $156.51 | $1.84 | |
| Market cap | $194.1B | $153M | |
| Net margin FY2025, SEC XBRL | +28.9% | -574.5% | GILD higher |
| Operating margin FY2025, SEC XBRL | +34.0% | -609.2% | GILD higher |
| ROE FY2025, SEC XBRL | +37.6% | -149.1% | GILD higher |
| ROA FY2025, SEC XBRL | +14.4% | -87.0% | GILD higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 2.22 | n/a | |
| Revenue growth (YoY) FY2025, SEC XBRL | +2.4% | -14.2% | GILD higher |
| Revenue CAGR (3y) SEC XBRL | +2.6% | n/a | |
| Dividend yield as of 2026-09-03 | +2.2% | n/a | |
| Dividend streak (yrs) SEC XBRL | 11 | 0 | GILD higher |
| Beta as of 2026-09-03 | 0.36 | 1.37 | |
| 1-year return as of 2026-10-20 close | +27.1% | -48.6% | GILD higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.